Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

MSK radiation oncologist Dr. Nadeem Riaz and colleagues discovered that bacteria inside tumors can undermine the effects of immunotherapy. In cancer research, failure can lead to an important ...

BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment Glutamine silences BATF2 and leads to a weakened immune response ...

HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...

HealthDay News — The rate of early termination or withdrawal in head and neck squamous cell carcinoma (HNSCC) clinical trials (CTs) has increased since 2000, with strategic decisions and poor ...

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...

Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most ...

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, affecting over half a million people each year and causing about 300,000 ...

Oropharyngeal cancer is a type of head and neck cancer. It affects the cells in the middle part of your throat, or what’s called the oropharynx. Early signs are easy to miss. “We can't see that area ...